Latest Payments News

Ricegrowers Limited announces a fully franked dividend of AUD 0.50 per Class B share for the fiscal year ending April 2025, accompanied by a dividend reinvestment plan offering a 3% discount.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology monoclonal antibody targeting VISTA, from Hummingbird Bioscience, marking a strategic pivot after recent setbacks. The company plans to initiate phase II trials in 2026, aiming to advance this novel cancer therapy toward commercialisation.

QuickFee Limited has successfully completed an oversubscribed Share Purchase Plan, raising a total of A$1.532 million alongside a recent placement, positioning the fintech for accelerated loan book expansion in the US and Australia.

Vanguard Investments Australia has announced estimated distribution amounts for over 30 ETFs, with payments scheduled for mid-July 2025. This detailed timetable offers investors clarity on income expectations and reinvestment options.

Magellan Asset Management announces a 12.25 cents per unit final distribution for its High Conviction Trust Active ETF for the six months ending June 2025, with key dates set for investors.

Magellan Asset Management announces a 7.33 cents per unit final distribution for the Airlie Australian Share Fund – Active ETF for the six months ended June 30, 2025, alongside key dates for investors to note.

Magellan Asset Management announces a 16.25 cents per unit final distribution for its Global Fund Active ETF for the six months ending June 2025, with key dates set for early July.

Findi Limited has secured a perpetual White Label ATM licence from the Reserve Bank of India, removing renewal hurdles and deployment limits. This milestone positions Findi to accelerate its digital financial services expansion across India’s underbanked regions.

Xero has completed a significant A$1.85 billion institutional placement to fund its acquisition of Melio, aiming to enhance its accounting and payments platform in the US market. A complementary A$200 million Share Purchase Plan will offer retail investors a chance to participate.

Paradigm Biopharmaceuticals has acquired Proteobioactives, securing global rights to an oral combination therapy targeting early-stage osteoarthritis in humans and animals, complementing its injectable PPS phase 3 program.

Civmec Limited has agreed to acquire Luerssen Australia for AUD 20 million, a move set to consolidate its position as a sovereign Australian shipbuilder and enhance its capabilities in naval vessel production.

Audinate Group Limited has acquired Iris, a US-based SaaS platform for remote AV device control, in a deal valued up to US$28 million. This move strengthens Audinate’s video and control capabilities within its Dante ecosystem.